MIRA submits Phase 2a protocol to FDA for Ketamir-2 in CIPN

MIRA PHARMACEUTICALS, INC.

Phase 2a protocol (Mira-002) for oral NMDA receptor modulator Ketamir-2 in chemotherapy-induced peripheral neuropathy.
Randomized, double-blind, placebo-controlled, three-period crossover trial with 300 mg and 600 mg doses.
No FDA-approved therapies exist for CIPN; study targets 30–40% of chemo patients affected.
Phase 1 showed clean safety: no serious AEs or dose-limiting toxicities in 56 volunteers.
Trial to run at a leading U.S. cancer center; FDA acknowledged receipt of submission.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.